40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
View analysts' price targets and recommendations, and compare them with competitors.
$52.00
Lower upside than AR's upside of 54.83%.
Buy
Equal to AR's analyst recommendation of Buy.
Analyze analyst forecasts for the company and compare them with competitors.
7.91B
The estimated revenue has decreased from the previous period.
1.58B
The estimated EBITDA has decreased from the previous period.
5.21
The estimated EPS has decreased from the previous period.
1.38B
The estimated net income has decreased from the previous period.
-23.87M
The estimated EBIT has increased from the previous period.
1.37B
The estimated SG&A expenses have decreased from the previous period.
Analyze DCF forecasts for the company and compare them with competitors.
16.45B
Revenue has increased from the previous period.
15.56%
Revenue growth rate is unchanged from the previous period.
3.29B
EBITDA has increased from the previous period.
20.00%
EBITDA margin is unchanged from the previous period.
-49.64M
EBIT has decreased from the previous period.
-0.30%
EBIT margin is unchanged from the previous period.
3.34B
Depreciation has increased from the previous period.
174.70M
Total cash has increased from the previous period.
1.06%
Cash percentage is unchanged from the previous period.
2.34B
Receivables have increased from the previous period.
14.23%
Receivables percentage is unchanged from the previous period.
19.28M
Inventories have increased from the previous period.
0.12%
Inventory percentage is unchanged from the previous period.
756.23M
Accounts payable has increased from the previous period.
4.60%
Payables percentage is unchanged from the previous period.
-4.13B
Capital expenditure has increased from the previous period.
-25.11%
CapEx percentage is unchanged from the previous period.
12.06%
WACC is unchanged from the previous period.
16.87%
Cost of equity is unchanged from the previous period.
5.31%
Cost of debt is unchanged from the previous period.
2.64
Beta is unchanged from the previous period.
263.90M
Diluted shares outstanding is unchanged from the previous period.
6.68B
Total debt is unchanged from the previous period.
10.03B
Total equity is unchanged from the previous period.
16.71B
Total capital is unchanged from the previous period.
39.98%
Debt weighting is unchanged from the previous period.
60.02%
Equity weighting is unchanged from the previous period.
-45.41M
EBIAT has decreased from the previous period.
-1.05B
UFCF has decreased from the previous period.
0.50%
Long-term growth rate is unchanged from the previous period.
-12.22B
Terminal value is unchanged from the previous period.
-10.90B
Enterprise value is unchanged from the previous period.
6.68B
Net debt is unchanged from the previous period.
-17.58B
Equity value is unchanged from the previous period.
-66.63
Equity value per share is unchanged from the previous period.
